Silo pharma submits pre-investigational new drug application to fda for spc-15 as a treatment for ptsd and anxiety

Clinical roadmap unveiled for novel and proprietary intranasal ptsd treatment sarasota, fl, june 04, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its submission of a pre-investigational new drug (pre-ind) briefing package and meeting request to the u.s. food and drug administration (fda) for spc-15, silo's intranasal prophylactic treatment for post-traumatic stress disorder (ptsd) and stress-induced anxiety disorder. pre-clinical data indicate that spc-15 has additive benefits for combating stress-induced pathophysiology, both at the behavioral and neural levels.
SILO Ratings Summary
SILO Quant Ranking